Literature DB >> 27438598

Factors Affecting Patients' Perception On, and Adherence To, Anticoagulant Therapy: Anticipating the Role of Direct Oral Anticoagulants.

Ekta Y Pandya1, Beata Bajorek2,3.   

Abstract

The role of the direct oral anticoagulants (DOACs) in practice has been given extensive consideration recently, albeit largely from the clinician's perspective. However, the effectiveness and safety of using anticoagulants is highly dependent on the patient's ability to manage and take these complex, high-risk medicines. This structured narrative review explores the published literature to identify the factors underpinning patients' non-adherence to anticoagulants in atrial fibrillation (AF), and subsequently contemplates to what extent the DOACs might overcome the known challenges with traditional warfarin therapy. This review comprised a two-tier search of various databases and search platforms (CINAHL, Cochrane, Current Contents Connect, EMBASE, MEDLINE Ovid, EBSCO, PubMed, Google, Google Scholar) to yield 47 articles reporting patients perspectives on, and patients adherence to, anticoagulant therapy. The findings from the literature were synthesised under five interacting dimensions of adherence: therapy-related factors, patient-related factors, condition-related factors, social-economic factors and health system factors. Factors negatively affecting patients' day-to-day lives (especially regular therapeutic drug monitoring, dose adjustments, dietary considerations) predominantly underpin a patient's reluctance to take warfarin therapy, leading to non-adherence. Other patient-related factors underpinning non-adherence include patients' perceptions and knowledge about the purpose of anticoagulation; understanding of the risks and benefits of therapy; socioeconomic status; and expectations of care from health professionals. In considering these findings, it is apparent that the DOACs may overcome some of the barriers to traditional warfarin therapy at least to an extent, particularly the need for regular monitoring, frequent dose adjustment and dietary considerations. However, their high cost, twice-daily dosing and gastrointestinal adverse effects may present additional challenges for patients and health systems. The review highlights the need to explicitly incorporate patients' perspectives in decision-making processes for anticoagulant selection, to obtain optimum adherence and treatment outcomes. Further studies should explore resources that can better engage patients in decision making around the selection of anticoagulant therapy.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 27438598     DOI: 10.1007/s40271-016-0180-1

Source DB:  PubMed          Journal:  Patient        ISSN: 1178-1653            Impact factor:   3.883


  78 in total

1.  Evaluation of reasons for dabigatran discontinuation in a community hospital and anticoagulation clinic.

Authors:  Ashley Jacobs; Dustin Linn; Brook Sipe; Angel Heyerly; Gordon Bokhart
Journal:  Hosp Pharm       Date:  2014-02

Review 2.  Shared decision making in atrial fibrillation: where we are and where we should be going.

Authors:  Luke Seaburg; Erik P Hess; Megan Coylewright; Henry H Ting; Christopher J McLeod; Victor M Montori
Journal:  Circulation       Date:  2014-02-11       Impact factor: 29.690

Review 3.  2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the Heart Rhythm Society.

Authors:  Craig T January; L Samuel Wann; Joseph S Alpert; Hugh Calkins; Joaquin E Cigarroa; Joseph C Cleveland; Jamie B Conti; Patrick T Ellinor; Michael D Ezekowitz; Michael E Field; Katherine T Murray; Ralph L Sacco; William G Stevenson; Patrick J Tchou; Cynthia M Tracy; Clyde W Yancy
Journal:  J Am Coll Cardiol       Date:  2014-03-28       Impact factor: 24.094

4.  The potential use of decision analysis to support shared decision making in the face of uncertainty: the example of atrial fibrillation and warfarin anticoagulation.

Authors:  A Robinson; R G Thomson
Journal:  Qual Health Care       Date:  2000-12

5.  Adherence to anticoagulant treatment with dabigatran in a real-world setting.

Authors:  S Schulman; B Shortt; M Robinson; J W Eikelboom
Journal:  J Thromb Haemost       Date:  2013-07       Impact factor: 5.824

6.  Risk factors for nonadherence to warfarin: results from the IN-RANGE study.

Authors:  Alec B Platt; A Russell Localio; Colleen M Brensinger; Dean G Cruess; Jason D Christie; Robert Gross; Catherine S Parker; Maureen Price; Joshua P Metlay; Abigail Cohen; Craig W Newcomb; Brian L Strom; Mitchell S Laskin; Stephen E Kimmel
Journal:  Pharmacoepidemiol Drug Saf       Date:  2008-09       Impact factor: 2.890

7.  Adherence to dabigatran therapy and longitudinal patient outcomes: insights from the veterans health administration.

Authors:  Supriya Shore; Evan P Carey; Mintu P Turakhia; Cynthia A Jackevicius; Fran Cunningham; Louise Pilote; Steven M Bradley; Thomas M Maddox; Gary K Grunwald; Anna E Barón; John S Rumsfeld; Paul D Varosy; Preston M Schneider; Lucas N Marzec; P Michael Ho
Journal:  Am Heart J       Date:  2014-04-05       Impact factor: 4.749

Review 8.  Medication adherence: its importance in cardiovascular outcomes.

Authors:  P Michael Ho; Chris L Bryson; John S Rumsfeld
Journal:  Circulation       Date:  2009-06-16       Impact factor: 29.690

9.  A patient decision aid to support shared decision-making on anti-thrombotic treatment of patients with atrial fibrillation: randomised controlled trial.

Authors:  Richard G Thomson; Martin P Eccles; I Nick Steen; Jane Greenaway; Lynne Stobbart; Madeleine J Murtagh; Carl R May
Journal:  Qual Saf Health Care       Date:  2007-06

10.  Patient perspective on the management of atrial fibrillation in five European countries.

Authors:  Ameet Bakhai; Anna Sandberg; Thomas Mittendorf; Wolfgang Greiner; André M S Oberdiek; Patrizia Berto; Edith Franczok; Trudie Lobban; Jose L Zamorano
Journal:  BMC Cardiovasc Disord       Date:  2013-12-01       Impact factor: 2.298

View more
  10 in total

1.  Health Literacy and Awareness of Atrial Fibrillation.

Authors:  Stephanie R Reading; Alan S Go; Margaret C Fang; Daniel E Singer; In-Lu Amy Liu; Mary Helen Black; Natalia Udaltsova; Kristi Reynolds
Journal:  J Am Heart Assoc       Date:  2017-04-11       Impact factor: 5.501

2.  Development of a New Patient-Reported Medication Adherence Instrument: Concerns Influencing Medication Adherence.

Authors:  Sonal Ghura Mansukhani; Elizabeth A MacLean; Laura L Manzey; Carl J Possidente; Joseph C Cappelleri; Linda S Deal
Journal:  Patient Prefer Adherence       Date:  2021-09-09       Impact factor: 2.711

3.  Adherence is an optimal factor for maximizing the effective and safe use of oral anticoagulants in patients with atrial fibrillation.

Authors:  So-Young Yang; Dong-Won Kang; Jin Hyun Nam; Eue-Keun Choi; Eui-Kyung Lee; Ju-Young Shin; Sun-Hong Kwon
Journal:  Sci Rep       Date:  2022-03-01       Impact factor: 4.996

4.  Optimizing adherence and persistence to non-vitamin K antagonist oral anticoagulant therapy in atrial fibrillation.

Authors:  José Maria Farinha; Ian D Jones; Gregory Y H Lip
Journal:  Eur Heart J Suppl       Date:  2022-02-14       Impact factor: 1.803

5.  Contemporary utilization of antithrombotic therapy for stroke prevention in patients with atrial fibrillation: an audit in an Australian hospital setting.

Authors:  Ekta Yogeshkumar Pandya; Elizabeth Anderson; Clara Chow; Yishen Wang; Beata Bajorek
Journal:  Ther Adv Drug Saf       Date:  2017-12-13

Review 6.  Single-incision laparoscopy surgery: a systematic review.

Authors:  Sasan Saeed Far; Sepide Miraj
Journal:  Electron Physician       Date:  2016-10-25

7.  Characteristics Associated With Facebook Use and Interest in Digital Disease Support Among Older Adults With Atrial Fibrillation: Cross-Sectional Analysis of Baseline Data From the Systematic Assessment of Geriatric Elements in Atrial Fibrillation (SAGE-AF) Cohort.

Authors:  Molly E Waring; Mellanie T Hills; Darleen M Lessard; Jane S Saczynski; Brooke A Libby; Marta M Holovatska; Alok Kapoor; Catarina I Kiefe; David D McManus
Journal:  JMIR Cardio       Date:  2019-11-14

8.  Antithrombotic Preventive Medication Prescription Redemption and Socioeconomic Status in Hungary in 2016: A Cross-Sectional Study.

Authors:  Attila Juhász; Csilla Nagy; Orsolya Varga; Klára Boruzs; Mária Csernoch; Zoltán Szabó; Róza Ádány
Journal:  Int J Environ Res Public Health       Date:  2020-09-19       Impact factor: 3.390

9.  A Survey of Pharmacogenomics Testing Among Physicians, Pharmacists, and Researchers From China.

Authors:  Chengxian Guo; Biwen Hu; Chengjun Guo; Xiangguang Meng; Yun Kuang; Longjian Huang; Danling Wang; Kangwei Xu; Yanlin Zhao; Guoping Yang; Weimin Cai; Yan Shu
Journal:  Front Pharmacol       Date:  2021-07-12       Impact factor: 5.810

10.  Cost Conversations About Anticoagulation Between Patients With Atrial Fibrillation and Their Clinicians: A Secondary Analysis of a Randomized Clinical Trial.

Authors:  Celia C Kamath; Rachel Giblon; Marlene Kunneman; Alexander I Lee; Megan E Branda; Ian G Hargraves; Angela L Sivly; Fernanda Bellolio; Elizabeth A Jackson; Bruce Burnett; Haeshik Gorr; Victor D Torres Roldan; Gabriella Spencer-Bonilla; Nilay D Shah; Peter A Noseworthy; Victor M Montori; Juan P Brito
Journal:  JAMA Netw Open       Date:  2021-07-01
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.